PDL BioPharma news from FierceBiotech
NewsBMS inks $710M development deal with PDL
Bristol-Myers Squibb is paying $30 million upfront in a licensing deal for PDL BioPharma's Read more...
PDL spins off biotech biz
After struggling for months to sell the company or some of its assets, PDL BioPharma has announced plans to spin off its biotech operations into a publicly-traded company. The new company will be Read more...
ALSO NOTED: PDL offers bonuses to top execs; Radius earns $28.3M for milestone;Cytokinetics surges on positive data; and much m
> PDL BioPharma says it will pay four top executives nearly $1 million in bonuses through the end of next year to keep them on board as the company undergoes a transformation into an antibody Read more...
PDL BioPharma puts out 'for sale' sign
The troubled PDL BioPharma has put out the 'for sale' sign in an attempt to find a buyer for the company as a whole or of its key assets. This comes in addition to an earlier announcement that PDL Read more...
In last act, PDL chief takes out the axe
Mark McDade has already announced that he's leaving his post as CEO of PDL BioPharma at the end of the year. And last night he Read more...
PDL chief resigns in wake of investor wrangle
Another biotech CEO bites the dust after tangling with a key investor. PDL BioPharma's CEO has decided to step aside Read more...
Biotech CEOs face rising fury of angry investors
The San Francisco Chronicle reports that a growing number of biotech execs have had to ward off the angry attacks of shareholder activists who protest the way they're running their companies. Read more...
| Press ReleasesPRESS RELEASE: PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets REDWOOD CITY, Calif., October 01, 2007 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) today announced that its board of Read more... PRESS RELEASE: PDL BioPharma Announces Significant Strategic and Portfolio Changes PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development - Company Plans Sale of Commercial Operations - FREMONT, Calif., Aug. 28 -- PDL Read more... |
Get more PDL BioPharma coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets